MetLife Investment Management’s Cue Biopharma CUE Stock Holding History

MetLife Investment Management’s Portfolio CUE Stock Details CUE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-617	Closed	-$67.6K	–	2910
2023 Q2	$67.6K	Buy	+617	New	+$72.5K	﹤0.01%	2856
2022 Q1	–	Sell	-394	Closed	-$134K	–	2740
2021 Q4	$134K	Buy	394 +182	+86%	+$70.4K	﹤0.01%	2292
2021 Q3	$92.5K	Sell	212 -218	-51%	-$76K	﹤0.01%	2472
2021 Q2	$150K	Hold	430	–	–	﹤0.01%	2322
2021 Q1	$158K	Buy	430 +3	+0.7%	+$1.24K	﹤0.01%	2170
2020 Q4	$160K	Hold	427	–	–	﹤0.01%	2100
2020 Q3	$193K	Hold	427	–	–	﹤0.01%	1884
2020 Q2	$314K	Buy	427 +93	+28%	+$67.4K	﹤0.01%	1630
2020 Q1	$142K	Hold	334	–	–	﹤0.01%	1878
2019 Q4	$159K	Buy	+334	New	+$105K	﹤0.01%	2105

Other funds holding CUE

SPC

Slate Path Capital New York $6.73B AUM 95.97% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

RSWM

Robertson Stephens Wealth Management San Francisco, California $3.57B AUM 28.36% 1-Year Est. Return

MAM

Monaco Asset Management Monaco $542M AUM 54.4% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

MetLife Investment Management's CUE Position: Q3 2023 in Review

MetLife Investment Management sold out of Cue Biopharma (CUE) in Q3 2023, closing a stake of 617 shares — an estimated $67.6K sold.

MetLife Investment Management first reported a position in CUE in Q4 2019 and held it in 10 quarters. The position peaked at $314K in Q2 2020. 75 funds tracked by Wall St. Rank hold CUE as of Q3 2023.

MetLife Investment Management reported no remaining Cue Biopharma position as of Q3 2023 after selling out during the quarter.
MetLife Investment Management sold 617 Cue Biopharma shares in Q3 2023, an estimated $67.6K.
MetLife Investment Management first reported a position in Cue Biopharma in Q4 2019 and held it in 10 quarters.
MetLife Investment Management's Cue Biopharma position peaked at $314K in Q2 2020.
75 funds tracked by Wall St. Rank held Cue Biopharma as of Q3 2023.

Based on MetLife Investment Management's 13F filing for Q3 2023, filed 14 Nov 2023.